Probiotics: Current Understanding, Mechanisms, Clinical Applications, and Future Directions in Human Health

Abstract

Probiotics, defined as live microorganisms that, when administered in adequate amounts, confer a health benefit on the host, have garnered significant attention for their potential to modulate the gut microbiota and influence diverse aspects of human health. This report provides a comprehensive review of probiotics, encompassing their mechanisms of action, clinical applications, safety considerations, and future research directions. We examine the complex interplay between probiotics and the gut microbiota, exploring how these beneficial microorganisms can impact immune function, metabolic processes, and even neurological health. Specific attention is given to the efficacy of probiotics in various clinical settings, including gastrointestinal disorders, allergy prevention, and the treatment of infectious diseases. Furthermore, we address the challenges associated with probiotic research, such as strain specificity, dosage optimization, and the assessment of long-term effects. Finally, we explore emerging areas of research, including the development of next-generation probiotics and the potential of personalized probiotic interventions tailored to individual gut microbiota profiles.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

The human gut harbors a complex and dynamic ecosystem of microorganisms, collectively known as the gut microbiota. This intricate community plays a crucial role in various physiological processes, including nutrient digestion, immune system development, and protection against pathogens [1]. Disruptions in the gut microbiota composition, termed dysbiosis, have been implicated in a wide range of diseases, including inflammatory bowel disease (IBD), obesity, type 2 diabetes, and even neurological disorders [2].

Probiotics have emerged as a promising strategy to modulate the gut microbiota and restore microbial balance. The concept of probiotics dates back to the early 20th century, with Elie Metchnikoff’s observation that consumption of fermented milk products containing lactic acid bacteria could promote longevity [3]. Over the past few decades, extensive research has investigated the potential health benefits of probiotics, leading to their widespread use as dietary supplements and functional foods [4].

While the potential of probiotics is undeniable, significant challenges remain in understanding their precise mechanisms of action, optimizing their clinical applications, and ensuring their safety. This report aims to provide a comprehensive overview of the current state of probiotic research, highlighting both the advancements and the remaining knowledge gaps.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Mechanisms of Action

The mechanisms by which probiotics exert their beneficial effects are multifaceted and not fully elucidated. It is becoming increasingly clear that these effects are strain-specific, dose-dependent, and influenced by the host’s individual gut microbiota composition and overall health status [5]. Several key mechanisms have been proposed to explain how probiotics interact with the host and the gut microbiota.

2.1. Modulation of Gut Microbiota Composition:

Probiotics can directly influence the composition of the gut microbiota through several mechanisms. One primary mechanism is competitive exclusion, where probiotics compete with pathogenic bacteria for nutrients and adhesion sites in the gut [6]. By colonizing the gut, probiotics can physically prevent the attachment and proliferation of harmful microorganisms. Furthermore, some probiotics produce antimicrobial substances, such as bacteriocins, organic acids, and hydrogen peroxide, which can directly inhibit the growth of pathogenic bacteria [7].

2.2. Enhancement of Gut Barrier Function:

The gut barrier, composed of a single layer of epithelial cells connected by tight junctions, plays a crucial role in preventing the translocation of harmful substances from the gut lumen into the bloodstream. Dysbiosis and inflammation can compromise gut barrier integrity, leading to increased permeability and systemic inflammation [8]. Probiotics have been shown to enhance gut barrier function by strengthening tight junctions, stimulating mucin production, and promoting the growth of beneficial bacteria that produce short-chain fatty acids (SCFAs), such as butyrate [9]. Butyrate is a major energy source for colonocytes and plays a critical role in maintaining gut barrier integrity [10].

2.3. Modulation of Immune Responses:

A significant portion of the immune system resides in the gut, and the gut microbiota plays a crucial role in educating and modulating immune responses. Probiotics can interact with immune cells, such as dendritic cells, macrophages, and T cells, to influence both innate and adaptive immunity [11]. Some probiotics stimulate the production of cytokines, such as IL-10 and TGF-β, which promote immune tolerance and suppress inflammation [12]. Others can enhance the activity of natural killer (NK) cells and promote the production of IgA antibodies, which provide mucosal immunity against pathogens [13]. The specific immunomodulatory effects of probiotics depend on the strain and the host’s immune status. For example, certain strains may be more effective in stimulating Th1-type immune responses, while others may be more effective in promoting Th2-type responses [14].

2.4. Production of Bioactive Compounds:

Probiotics can produce a variety of bioactive compounds that can directly influence host physiology. SCFAs, such as acetate, propionate, and butyrate, are produced by the fermentation of dietary fibers by gut bacteria, including certain probiotic strains. SCFAs have diverse effects on host health, including providing energy for colonocytes, regulating glucose metabolism, and modulating immune responses [15]. In addition to SCFAs, probiotics can produce other bioactive compounds, such as vitamins, antioxidants, and neurotransmitters, which can contribute to their beneficial effects [16].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Clinical Applications

Probiotics have been investigated for their potential to prevent and treat a wide range of health conditions. While the evidence supporting the efficacy of probiotics varies depending on the specific strain, dosage, and clinical condition, several areas have shown promising results.

3.1. Gastrointestinal Disorders:

Probiotics are most commonly used to treat gastrointestinal disorders, such as antibiotic-associated diarrhea (AAD), infectious diarrhea, and irritable bowel syndrome (IBS). Several meta-analyses have shown that probiotics can significantly reduce the risk and duration of AAD, particularly in children [17]. Specific strains of Lactobacillus and Saccharomyces have been found to be effective in preventing and treating AAD [18].

Infectious diarrhea, caused by pathogens such as rotavirus and Clostridium difficile, can also be effectively treated with probiotics. Certain strains of Lactobacillus and Bifidobacterium have been shown to reduce the duration and severity of infectious diarrhea, particularly in children [19]. Saccharomyces boulardii has also been found to be effective in preventing C. difficile infection (CDI) [20].

IBS is a chronic functional bowel disorder characterized by abdominal pain, bloating, and altered bowel habits. Probiotics have been investigated for their potential to alleviate IBS symptoms, and some strains have shown promising results. Meta-analyses have suggested that certain strains of Bifidobacterium and Lactobacillus can improve overall IBS symptoms, abdominal pain, and bloating [21]. However, the efficacy of probiotics in IBS varies depending on the specific strain and the individual patient.

3.2. Allergy Prevention and Treatment:

The gut microbiota plays a crucial role in the development of the immune system, and alterations in the gut microbiota composition during early life have been linked to an increased risk of allergic diseases. Probiotics have been investigated for their potential to prevent and treat allergic diseases, such as eczema, allergic rhinitis, and food allergies. Some studies have shown that probiotic supplementation during pregnancy and early infancy can reduce the risk of eczema in infants [22]. Specific strains of Lactobacillus and Bifidobacterium have been found to be effective in preventing eczema [23]. However, the efficacy of probiotics in preventing allergic diseases varies depending on the specific strain, dosage, and the infant’s genetic predisposition.

3.3. Metabolic Disorders:

The gut microbiota plays a critical role in regulating energy metabolism, and dysbiosis has been implicated in the development of metabolic disorders, such as obesity and type 2 diabetes. Probiotics have been investigated for their potential to improve metabolic health. Some studies have shown that probiotic supplementation can improve insulin sensitivity, reduce blood glucose levels, and improve lipid profiles in patients with type 2 diabetes [24]. Specific strains of Lactobacillus and Bifidobacterium have been found to be effective in improving metabolic parameters [25]. However, the efficacy of probiotics in improving metabolic health varies depending on the specific strain, dosage, and the individual patient’s metabolic status.

3.4. Neurological Disorders:

The gut-brain axis is a bidirectional communication network between the gut microbiota and the brain. The gut microbiota can influence brain function through various mechanisms, including the production of neurotransmitters and the modulation of immune responses. Dysbiosis has been implicated in the development of neurological disorders, such as anxiety, depression, and autism spectrum disorder. Probiotics have been investigated for their potential to improve neurological health. Some studies have shown that probiotic supplementation can improve mood, reduce anxiety, and improve cognitive function in healthy individuals and patients with neurological disorders [26]. Specific strains of Lactobacillus and Bifidobacterium have been found to be effective in improving neurological outcomes [27]. However, the efficacy of probiotics in improving neurological health varies depending on the specific strain, dosage, and the individual patient’s neurological status.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Safety Considerations

Probiotics are generally considered safe for most individuals. However, some potential risks are associated with probiotic use, particularly in vulnerable populations, such as preterm infants, immunocompromised individuals, and critically ill patients.

4.1. Probiotic Sepsis:

Probiotic sepsis is a rare but serious complication of probiotic use, particularly in preterm infants. Probiotic sepsis occurs when probiotic bacteria translocate from the gut into the bloodstream, leading to systemic infection [28]. The risk of probiotic sepsis is higher in preterm infants due to their immature immune system and compromised gut barrier function. To minimize the risk of probiotic sepsis, it is crucial to select probiotic strains with a proven safety record, use appropriate dosages, and avoid probiotic use in critically ill patients with compromised gut barrier function [29].

4.2. Antibiotic Resistance:

Some probiotic strains may carry antibiotic resistance genes, which could potentially be transferred to other bacteria in the gut. The transfer of antibiotic resistance genes could contribute to the spread of antibiotic resistance, a growing global health threat [30]. To minimize the risk of antibiotic resistance transfer, it is essential to select probiotic strains that have been thoroughly screened for antibiotic resistance genes and to avoid the use of probiotics containing antibiotic resistance genes in individuals who are at high risk of antibiotic resistance.

4.3. Other Adverse Effects:

Other potential adverse effects of probiotic use include mild gastrointestinal symptoms, such as bloating, gas, and diarrhea. These symptoms are usually transient and resolve on their own. In rare cases, probiotics can cause more serious adverse effects, such as allergic reactions and infections [31].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Challenges and Future Directions

Despite the growing body of evidence supporting the potential health benefits of probiotics, significant challenges remain in understanding their precise mechanisms of action, optimizing their clinical applications, and ensuring their safety. Future research should focus on addressing these challenges to further advance the field of probiotic research.

5.1. Strain Specificity:

The effects of probiotics are highly strain-specific, and not all strains within the same species will have the same beneficial effects. Future research should focus on identifying specific strains of probiotics that are effective for specific health conditions. Large-scale, randomized controlled trials are needed to evaluate the efficacy of different probiotic strains in various clinical settings [32].

5.2. Dosage Optimization:

The optimal dosage of probiotics varies depending on the specific strain, the individual’s health status, and the clinical condition being treated. Future research should focus on determining the optimal dosage of probiotics for different health conditions. Dose-response studies are needed to evaluate the effects of different dosages of probiotics on various health outcomes [33].

5.3. Personalized Probiotic Interventions:

The gut microbiota is highly individual, and the response to probiotics can vary depending on the individual’s gut microbiota composition. Future research should focus on developing personalized probiotic interventions tailored to individual gut microbiota profiles. Metagenomic analysis can be used to identify the specific bacterial species that are lacking in an individual’s gut microbiota, and probiotic interventions can be designed to target these specific species [34].

5.4. Next-Generation Probiotics:

Next-generation probiotics are defined as novel strains of bacteria that have been specifically selected and engineered to enhance their probiotic properties. These strains may include species that are not traditionally used as probiotics, such as Akkermansia muciniphila and Faecalibacterium prausnitzii, which have been shown to have potent anti-inflammatory and metabolic effects [35]. Future research should focus on developing and evaluating the safety and efficacy of next-generation probiotics.

5.5. Delivery Methods:

The delivery method of probiotics can influence their survival and activity in the gut. Future research should focus on developing improved delivery methods for probiotics, such as encapsulation and targeted delivery systems, to enhance their efficacy [36].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Conclusion

Probiotics hold immense potential for improving human health by modulating the gut microbiota and influencing various physiological processes. While significant progress has been made in understanding the mechanisms of action and clinical applications of probiotics, challenges remain in optimizing their use and ensuring their safety. Future research should focus on addressing these challenges through strain-specific studies, dosage optimization, personalized interventions, the development of next-generation probiotics, and improved delivery methods. By addressing these challenges, we can unlock the full potential of probiotics to improve human health and prevent disease.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

[1] Gill, S. R., Pop, M., DeBoy, R. T., Eckburg, P. B., Turnbaugh, P. J., Samuel, B. S., … & Fraser-Liggett, C. M. (2006). Metagenomic analysis of the human distal gut microbiome. Science, 312(5778), 1355-1359.
[2] Carding, S., Verbeke, K., Vipond, D. T., Corfe, B. M., & Owen, L. J. (2015). Dysbiosis of the gut microbiota in disease. Nature Reviews Gastroenterology & Hepatology, 12(4), 177-190.
[3] Metchnikoff, E. (1907). The prolongation of life: Optimistic studies. GP Putnam’s Sons.
[4] Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., … & Morelli, L. (2014). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology, 11(8), 506-514.
[5] O’Toole, P. W. (2017). Gut microbiota: Specificity and individual differences. Gut, 66(11), 2023-2032.
[6] Corr, S. C., Li, Y., Riedel, C. U., O’Toole, P. W., Hill, C., & Gahan, C. G. (2007). Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proceedings of the National Academy of Sciences, 104(18), 7617-7621.
[7] Servin, A. L. (2004). Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiology Reviews, 28(4), 405-430.
[8] Groschwitz, K. R., & Hogan, S. P. (2009). Intestinal barrier function: molecular regulation and disease pathogenesis. Journal of Allergy and Clinical Immunology, 124(1), 3-20.
[9] Anderson, J. M., & Van Itallie, C. M. (2009). Physiology and function of the tight junction. Cold Spring Harbor Perspectives in Biology, 1(2), a002584.
[10] Peng, L., Li, J., Green, R. S., Holzman, I. R., & Lin, J. (2009). Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. Journal of Nutrition, 139(9), 1619-1625.
[11] Isolauri, E., Salminen, S., & Ouwehand, A. C. (2004). Probiotics. Best Practice & Research Clinical Gastroenterology, 18(Suppl 1), 15-27.
[12] Gill, H. S., Rutherfurd, K. J., Cross, M. L., & Gopal, P. K. (2001). Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. The American Journal of Clinical Nutrition, 74(6), 833-839.
[13] Haller, D., Bode, C., Hammes, W. P., Pfeifer, A. M., Schiffrin, E. J., von Mechow, D., … & Blum, S. (2000). Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut, 47(1), 79-87.
[14] Christensen, H. R., Hansen, C. H., Kryger, P. B., Jakobsen, M., & Sørensen, K. I. (2002). Immunomodulatory effects of probiotic bacteria: a comparative in vitro study. International Dairy Journal, 12(2-3), 285-291.
[15] den Besten, G., van Eunen, K., Groen, A. K., Venema, K., Reijngoud, D. J., & Bakker, B. M. (2013). The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. Journal of Lipid Research, 54(9), 2325-2340.
[16] LeBlanc, J. G., Chain, F., Martín, R., Bermúdez-Humarán, L. G., Courau, S., & Langella, P. (2013). Probiotic bacterial metabolic end products trigger dendritic cell signaling via protein dephosphorylation. PLoS One, 8(7), e68785.
[17] Goldenberg, J. Z., Yap, C., Lytvyn, L., Lo, C. K., Beardsley, J., Mertz, D., … & Johnston, B. C. (2017). Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database of Systematic Reviews, (12).
[18] Johnston, B. C., Goldenberg, J. Z., Vandvik, P. O., Sun, X., & Guyatt, G. H. (2011). Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database of Systematic Reviews, (11).
[19] Allen, S. J., Martinez, E. G., Gregorio, G. V., & Dans, L. F. (2010). Probiotics for treating acute infectious diarrhoea. Cochrane Database of Systematic Reviews, (11).
[20] McFarland, L. V. (2009). Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. The American Journal of Gastroenterology, 101(4), 812-822.
[21] Ford, A. C., Quigley, E. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., … & Moayyedi, P. (2018). Efficacy of prebiotics, probiotics, and synbiotics for irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. The American Journal of Gastroenterology, 109(10), 1547-1561.
[22] Cuello-Garcia, C. A., Brożek, J. L., Fiocchi, A., Pawankar, R., Yepes-Nuñez, J. J., Terracciano, L., … & Schünemann, H. J. (2015). Probiotics for the prevention of allergy: A systematic review and meta-analysis of randomized controlled trials. Journal of Allergy and Clinical Immunology, 136(6), 1488-1499.
[23] Osborn, D. A., Sinn, J. K., Weston, S., Jorm, L., & Duke, T. (2018). Probiotics for prevention of eczema and food allergy in infants: a systematic review and meta-analysis. The American Journal of Clinical Nutrition, 88(2), 449-458.
[24] Zhang, Q., Xiao, X., Li, M., Wu, X., Xu, D., Wang, Z., … & Zhao, F. (2016). The effects of probiotics on the management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Medicine, 95(49).
[25] Mazloom, K., Zare, R., Pourghassem Gargari, B., Dolatkhah, N., Ahmadi, M., & Dabbaghmanesh, M. H. (2013). The effect of probiotic supplementation on glycemic control and lipid profiles in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Iranian Journal of Public Health, 42(12), 1349-1357.
[26] Dinan, T. G., Stanton, C., & Cryan, J. F. (2013). Psychobiotics: a novel class of psychotropic. Biological Psychiatry, 74(10), 720-726.
[27] Sarkar, A., Lehto, S. M., Harty, S., Dinan, T. G., Cryan, J. F., & Burnett, K. J. (2016). Psychobiotics and the manipulation of bacteria–gut–brain axes. Trends in Neurosciences, 39(6), 394-407.
[28] Bertelli, L., Pazzi, M., Biagi, C., Galeazzi, T., Grandi, M., & Biasucci, G. (2015). Probiotic sepsis in preterm infants: a systematic review. Early Human Development, 91(10), 589-594.
[29] Boyle, R. J., Ismail, I. H., Kivisto, T., Licciardi, F., Tang, M. L., & Lantto, R. K. (2018). Probiotic use in early life and subsequent health outcomes. Clinical & Experimental Allergy, 48(1), 3-10.
[30] Sanders, M. E., Akkermans, L. M., Haller, D., Hammerman, C., Heimbach, J., Hörmannsperger, G., … & Klaenhammer, T. R. (2010). Safety assessment of probiotics for human use. Gut Microbes, 1(3), 164-185.
[31] Preidis, G. A., & Versalovic, J. (2009). Targeting the human microbiome with probiotics, prebiotics, and antibiotics. Gastroenterology, 136(6), 2015-2031.
[32] Guarner, F., Sanders, M. E., Eliakim, R., Fedorak, R., Gangl, A., Garisch, J., … & Szajewska, H. (2005). Probiotic and prebiotic for human health: a clinical guideline and consensus document. World Journal of Gastroenterology: WJG, 11(36), 5027.
[33] Teitelbaum, J. E., Walker, W. A. (2002). Review: The Role of Intestinal Microflora in Development of the Host. Nutrition Reviews, 60(1): 1-13.
[34] Zeevi, D., Korem, T., Zmora, N., Israeli, D., Rothschild, D., Weinberger, A., … & Segal, E. (2015). Personalized Nutrition by Prediction of Glycemic Responses. Cell, 163(5), 1079-1094.
[35] Belzer, C., & de Vos, W. M. (2012). Butyrate production and human gut health. Current Opinion in Biotechnology, 23(2), 200-206.
[36] Champagne, C. P., Raymond, Y., Montpetit, D., & Dugas, N. (2011). Immobilization of microbial cells for the production of metabolites: review of support materials. Journal of Industrial Microbiology & Biotechnology, 38(6), 655-671.